中國生物製藥(01177.HK):靜脈麻醉藥“鹽酸右美託咪定注射液”獲藥品註冊證書
格隆匯7月15日丨中國生物製藥(01177.HK)發佈公吿,集團開發的靜脈麻醉藥“鹽酸右美託咪定注射液”(商品名:長舒寧)已獲中國國家藥品監督管理局頒發藥品註冊證書。該產品按照化學藥品3類申報,視同通過仿製藥質量和療效一致性評價。
右美託咪定作為α2腎上腺素能受體激動劑,具有中樞性抗交感、抗焦慮和鎮靜作用;可用於全身麻醉、氣管內插管行呼吸機治療和有創檢查的鎮靜,還可用於心血管手術麻醉以及圍術期麻醉合併用藥。右美託咪定在鎮靜催眠過程中不會產生呼吸抑制,被多個國內外指南所推薦,已被納入國家醫保,是臨牀主流麻醉用藥之一。該產品獲批上市,將加強集團在麻醉領域的實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.